Does semaglutide increase resting heart rate?

Yes, semaglutide can increase resting heart rate. The current Wegovy label reports a mean rise of 1 to 4 beats per minute over placebo in adult weight-reduction trials. That is a group average, not a personal forecast. Larger one-time increases occurred in both the semaglutide and placebo groups, so clinicians look for a pattern rather than interpreting one reading alone.

How much can Wegovy raise heart rate?

The average increase was 1 to 4 beats per minute over placebo in adult trials. At some visit, 41% of adults receiving Wegovy injection had a rise of 10 to 19 bpm, versus 34% on placebo; rises of at least 20 bpm occurred in 26% versus 16%. Those larger figures are maximum changes recorded at any visit, not sustained averages.

Can semaglutide cause palpitations?

Palpitations or a racing heartbeat at rest are symptoms the Wegovy label specifically tells clinicians to discuss with patients. A palpitation is the feeling of pounding, fluttering or skipping; it is not a diagnosis of an abnormal rhythm. A clinician may compare the symptom with pulse readings, an ECG and the timing of other symptoms to understand what it represents.

Does a faster heart rate mean semaglutide is harming the heart?

Not by itself. Heart rate is one measurement, while heart attack, stroke and cardiovascular death are separate outcomes. SELECT found fewer of those major events with branded semaglutide than placebo in a specific high-risk group, even though semaglutide trials also recorded small average pulse increases. A sustained or symptomatic rise still needs individual clinical review.

When does the Wegovy label say treatment should stop?

The label says clinicians should discontinue Wegovy when a patient has a sustained increase in resting heart rate. It does not define one universal bpm threshold or a set number of days. That makes the trend, accompanying symptoms, other medicines and the clinical context more useful than a single watch reading when the prescriber makes the decision.

Does tirzepatide also increase heart rate?

Yes, a small mean increase appears in tirzepatide data too. The current Zepbound prescribing information, revised August 2026, reports an average rise of 1 to 3 beats per minute, compared with no mean increase in placebo groups. That parallel figure does not prove the medicines are interchangeable, because their receptors, trial programs and individual prescribing considerations differ.

Does Semaglutide Increase Heart Rate?

Yes. If the question is does semaglutide increase heart rate, the plain answer is yes, usually by a few beats per minute on average. Most people will not feel a change that small. But an average can hide larger rises, and a pounding or racing heartbeat at rest is not something the label brushes aside.

The useful distinction is between a modest number measured across a trial and a persistent change in one person. The first is expected. The second is something a prescriber needs to interpret in context.

Does semaglutide increase heart rate in the trials?

Resting heart rate is simply the number of times the heart beats in a minute while the body is not exerting itself. In the Wegovy prescribing information revised June 2026, adults receiving the injection in weight-reduction trials averaged 1 to 4 beats per minute (bpm) more than placebo. Findings were similar with Wegovy tablets.

Some people had a larger change at least once. A maximum rise of 10 to 19 bpm at any visit occurred in 41% of adults receiving the injection and 34% receiving placebo. A rise of at least 20 bpm occurred in 26% and 16%, respectively. Those are one-visit maximums, not the usual sustained increase for every person.

STEP 1 helps show where the average came from. This 68-week trial included 1,961 adults with overweight or obesity and no diabetes, and change in pulse was a prespecified safety measure. In the trial supplement, pulse rose 3.52 bpm with semaglutide and fell 0.74 bpm with placebo at week 68, a placebo-adjusted difference of 4.26 bpm (Wilding and colleagues, New England Journal of Medicine, 2021).

A 2026 analysis that combined 12 randomized-trial reports reached much the same neighborhood. Semaglutide was associated with a mean 3.35-bpm increase over placebo; the 95% confidence interval—the range most compatible with the data—was 1.69 to 5.01 bpm (Zhang and colleagues, European Journal of Medical Research, 2026).

What the newest heart-sensor study adds

As of September 18, 2026, the day this article was written, a study published September 15 adds unusually detailed heart-rate data. Researchers compared existing records from 666 people with heart failure who had implanted defibrillators or resynchronization devices. Among the 111 who started a GLP-1 medicine, 95% used semaglutide; their device readings averaged 1.46 bpm higher during the day and 2.12 bpm higher at night than matched controls (Fussing and colleagues, European Journal of Heart Failure, 2026).

That study is useful because an implanted device measures continuously, not only during a clinic visit. It is also narrow: these patients already had heart failure and cardiac devices, and treatment was not randomly assigned. The authors said larger studies are needed before the clinical meaning is clear.

Why the pulse may rise

Semaglutide activates the GLP-1 receptor, a docking point for a natural gut hormone involved in appetite and blood sugar. The exact heart-rate mechanism in people is still being worked out.

One clue comes from the sinus node, the heart's natural pacemaker. A 2024 laboratory study found GLP-1 receptors in pig pacemaker cells and showed that GLP-1 sped isolated pig hearts; blocking that receptor stopped the effect (Lubberding and colleagues, Cardiovascular Research, 2024). That supports a direct effect on the heart's timing cells, but an animal mechanism cannot predict how much one person's pulse will change.

Palpitations are a feeling, not a reading

Palpitations mean an awareness of the heartbeat: pounding, fluttering, skipping or racing. They do not automatically mean the measured heart rate is high, and a high reading does not by itself identify an abnormal rhythm. An electrocardiogram, or ECG—a tracing of the heart's electrical activity—is one way clinicians sort out that difference.

The Wegovy label tells clinicians to have patients report palpitations or a racing heartbeat while at rest. It also calls for heart-rate monitoring at regular clinical intervals. Chest pain, fainting or severe shortness of breath alongside a racing heartbeat calls for urgent medical assessment rather than waiting for a routine follow-up.

A small rise is not the same as heart harm

Heart rate is one measurement. Heart attack, stroke and cardiovascular death are different outcomes, and they have to be studied directly. In SELECT, a trial of 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, those major events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over an average 39.8 months (Lincoff and colleagues, New England Journal of Medicine, 2023).

That does not make a persistent racing pulse irrelevant. It means the small average pulse increase and the trial's cardiovascular outcome can both be true. The SELECT trial results explain that study in detail, while semaglutide and heart health covers who the broader evidence actually fits.

How tirzepatide compares

This is not unique to semaglutide. The current Zepbound prescribing information, revised August 2026, reports a mean heart-rate increase of 1 to 3 bpm with tirzepatide, compared with no mean increase on placebo. That one-line comparison does not make the two medicines interchangeable; tirzepatide's heart evidence comes from different trials and populations.

What a sustained increase means

The Wegovy label says clinicians should discontinue the medicine if a patient has a sustained rise in resting heart rate. It does not supply one universal bpm cutoff or a fixed number of days that defines “sustained.” One watch alert therefore is not the same thing as the pattern the label describes.

A prescriber can look at the trend, symptoms, timing around dose changes, other medicines and possible fluid loss from vomiting or diarrhea. That context matters because the right response to a small stable change may differ from the response to a continuing rise with symptoms. The label leaves that judgment with the clinician.

What this means for compounded semaglutide

The figures above come from trials and labeling for branded semaglutide. Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Those brand-specific trial numbers cannot establish identical results for a compounded preparation.

A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies. Heart-rate history, current medicines and any symptoms belong in that review.